Gene · 9869
Papers2,616
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
561 to 580 of 2,616
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A novel chromatin regulator-related immune checkpoint related gene prognostic signature and potential candidate drugs for endometrial cancer patients. | Hereditas | 2022 | 36253800 | PubTator, text mining | PubMed |
| Histone lysine methylation patterns in prostate cancer microenvironment infiltration: Integrated bioinformatic analysis and histological validation. | Front Oncol | 2022 | 36237332 | PubTator, text mining | PubMed |
| Unraveling tumor microenvironment heterogeneity in malignant pleural mesothelioma identifies biologically distinct immune subtypes enabling prognosis determination. | Front Oncol | 2022 | 36237331 | PubTator, text mining | PubMed |
| NSD2 as a Promising Target in Hematological Disorders. | Int J Mol Sci | 2022 | 36232375 | PubTator, text mining | PubMed |
| Genetic Analysis Implicates Dysregulation of SHANK2 in Renal Cell Carcinoma Progression. | Int J Environ Res Public Health | 2022 | 36231770 | PubTator, text mining | PubMed |
| Utilizing an Endogenous Progesterone Receptor Reporter Gene for Drug Screening and Mechanistic Study in Endometrial Cancer. | Cancers (Basel) | 2022 | 36230806 | PubTator, text mining | PubMed |
| Molecular Characterization Reveals Subclasses of 1q Gain in Intermediate Risk Wilms Tumors. | Cancers (Basel) | 2022 | 36230794 | PubTator, text mining | PubMed |
| The emerging therapeutic target of dynamic and reversible N6-methyladenosine modification during cancer development. | Front Oncol | 2022 | 36226062 | PubTator, text mining | PubMed |
| The regulation and potential roles of m6A modifications in early embryonic development and immune tolerance at the maternal-fetal interface. | Front Immunol | 2022 | 36225914 | PubTator, text mining | PubMed |
| Current understanding of epigenetics role in melanoma treatment and resistance. | Cancer Cell Int | 2022 | 36224606 | PubTator, text mining | PubMed |
| Role of K63-linked ubiquitination in cancer. | Cell Death Discov | 2022 | 36202787 | PubTator, text mining | PubMed |
| RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer. | J Clin Invest | 2022 | 36201246 | PubTator, text mining | PubMed |
| Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond. | Front Pharmacol | 2022 | 36188615 | PubTator, text mining | PubMed |
| Clustering of Chromatin Remodeling Enzymes Predicts Prognosis and Clinical Benefit of Therapeutic Strategy in Pancreatic Cancer. | Int J Med Sci | 2022 | 36185333 | PubTator, text mining | PubMed |
| BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies. | Curr Treat Options Oncol | 2022 | 36181568 | PubTator, text mining | PubMed |
| Akt: a key transducer in cancer. | J Biomed Sci | 2022 | 36180910 | PubTator, text mining | PubMed |
| Targeting epigenetic regulators for inflammation: Mechanisms and intervention therapy. | MedComm (2020) | 2022 | 36176733 | PubTator, text mining | PubMed |
| Mapping the interaction between Trim28 and the KRAB domain at the center of Trim28 silencing of endogenous retroviruses. | Protein Sci | 2022 | 36173157 | PubTator, text mining | PubMed |
| Crosstalk between age accumulated DNA-damage and the SIRT1-AKT-GSK3ß axis in urine derived renal progenitor cells. | Aging (Albany NY) | 2022 | 36170022 | PubTator, text mining | PubMed |
| Z-nucleic acids: Uncovering the functions from past to present. | Eur J Immunol | 2022 | 36165274 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9869/papers?page=29